Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 526 - 550 of 15398 in total

Daptomycin

Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked...
Approved
Investigational
Matched Description: … -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). ... with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and ... [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Human botulinum neurotoxin A/B immune globulin

Infant botulism is a rare infectious disease occurring in infants in which Clostridium botulinum colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding...
Approved
Matched Description: … Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma ... infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and ... ptosis, feeding difficulties) which may progress to more serious symptoms such as respiratory arrest and …

Tezacaftor

Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …

Tyrothricin

Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Description: … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved ... By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and ... in cytokine signalling and hematopoiesis. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed ... There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated …

Testolactone

An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Approved
Investigational
Matched Description: … An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer …

Lixisenatide

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU. …
Matched Mixtures name: … LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide …

Treprostinil

Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Description: … The first generic form of treprostinil became available in 2019.[A248775] ... systemic arterial vascular beds and the inhibition of platelet aggregation. ... is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of pulmonary and …
Matched Categories: … Blood and Blood Forming Organs …

Holcus lanatus pollen

Holcus lanatus pollen is the pollen of the Holcus lanatus plant. Holcus lanatus pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Standardized and Non-Standardized Coastal Grasses ... Mixture of Twenty-Two Standardized and Non-Standardized Grasses …

Chromium nicotinate

Approved
Experimental

Cyd dengue virus serotype 1 live (attenuated) antigen

Approved
Matched Mixtures name: … DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION ... DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION …

Cyd dengue virus serotype 2 live (attenuated) antigen

Approved
Matched Mixtures name: … DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION ... DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION …

Levonordefrin

Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Approved
Matched Description: … Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. …
Matched Mixtures name: … Mepivacaine Hydrochloride and Levonordefrin …
Matched Categories: … Epinephrine and similars …

Cenegermin

Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Fosdenopterin

Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites ... paraplegia, myoclonus, and opisthotonus. ... a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Bioallethrin

Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms...
Approved
Experimental
Matched Iupac: … 2-methyl-4-oxo-3-(prop-2-en-1-yl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane …
Matched Description: … Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an ... synthetic pyrethroid used as a pesticide against household pest insects such as mosquitoes, houseflies and …
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …

Methimazole

Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Iupac: … 1-methyl-2,3-dihydro-1H-imidazole-2-thione …
Matched Description: … [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now ... potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and ... [L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and …
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lorazepam

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Raloxifene

Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM....
Approved
Investigational
Matched Description: … uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. ... and it does not cause endometrial proliferation. ... generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Etonogestrel

Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Approved
Investigational
Matched Description: … [A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA …
Matched Mixtures name: … Etonogestrel and Ethinyl Estradiol ... Etonogestrel and Ethinyl Estradiol Vaginal ... Etonogestrel and Ethinyl Estradiol Vaginal Ring …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Combination Contraceptives (with Estrogen and derivatives) …

Trimipramine

Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Approved
Matched Description: … Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. …
Matched Categories: … Tricyclics and Other Norepinephrine-reuptake Inhibitors …

Pentoxifylline

Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties.[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for its possible...
Approved
Investigational
Matched Description: … [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced ... also has both anti-oxidant and anti-inflammatory properties. ... Pharmaceuticals and APOTEX have been available since the late 1990s. …

Glimepiride

First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Iupac: … 3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)- …
Matched Description: … long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. ... worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and ... present,[A177715] as they work by stimulating the release of insulin from the pancreatic beta cells and …
Matched Mixtures name: … Pioglitazone and Glimepiride ... Pioglitazone and Glimepiride ... Pioglitazone hydrochloride and glimepiride …
Matched Categories: … Alimentary Tract and Metabolism ... glimepiride and pioglitazone ... glimepiride and rosiglitazone …

Loxoprofen

Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Matched Iupac: … 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid …
Matched Description: … , and as Oxeno in Argentina. ... It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India …
Matched Categories: … Topical Products for Joint and Muscular Pain …
Displaying drugs 526 - 550 of 15398 in total